Evidence map›Paper›PMID 41775866›Full record

ArticleNPJ precision oncology2026

Ensemble learning on serum metabolic fingerprints for early detection of lung adenocarcinoma.

Chenlei Cai, Weijie Xu, Shuo Yang, Jia Yu, Lei Wang, Shengxiang Ren

Abstract read
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chenlei Cai *Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. chenlei_cai@tongji.edu.cn.
Weijie Xu *Department of Clinical Laboratory, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Shuo YangDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Jia YuDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Lei WangDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. wangleixxxn@163.com.
Shengxiang RenDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. harry_ren@tongji.edu.cn.

Funding

the National Natural Science Foundation of China 82404096the Science and Technology Commission of Shanghai Municipality 24Y12800300
6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality worldwide, highlighting the urgent need for non-invasive strategies for early detection. Here, we present a machine learning-assisted metabolomics approach for the early detection of LUAD. Untargeted metabolomic profiling was performed on 199 serum samples from healthy individuals, patients with lung precancerous lesions, and those with stage I LUAD. An ensemble machine learning workflow was developed to identify metabolite panels capable of discriminating clinical status with high accuracy. We observed progressive metabolic alterations in bile acid, lipid, amino acid, and purine metabolism during LUAD initiation and stepwise progression. Notably, ensemble learning identified a six-metabolite panel, including 12-hydroxydodecanoic acid, hypoxanthine, xanthosine, cholic acid, agmatine, and paraxanthine, for accurate detection of early-stage LUAD, and a distinct four-metabolite panel, comprising 7-α,27-dihydroxycholesterol, 11-undecanedicarboxylic acid, biliverdin, and Prolyl-Valine, for precise differentiation between pre-invasive and invasive lesions. Both panels demonstrated promising diagnostic potential, with performance metrices comparing favorably to established methodologies within the current study cohort. This study delineates the evolutionary trajectory of the serum metabolome associated with early LUAD pathogenesis and provides promising biomarkers for non-invasive early detection.

Identifiers

PMID41775866
PMCPMC13076990

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.